AUS
NZ
UK
CA
USA
IND
Highlights
- Wellnex Life (ASX:WNX) directors commit $1.5 million to the entitlement offer.
- Capital raised will support debt reduction, an acquisition, and AIM listing plans.
- Strong revenue growth and licensing expansion reinforce the company’s momentum.
Wellnex Life (ASX:WNX) is making strategic moves to fuel its growth ambitions, with its directors pledging at least $1.5 million as part of the company’s current entitlement offer. This initiative is a significant step toward funding its expansion, including a planned dual listing on the AIM market of the London Stock Exchange.
The entitlement offer, priced at $0.65 per share on a 1:1 basis, remains open until February 26, allowing eligible shareholders to participate and subscribe for additional shares. The company has already secured conditional binding commitments of $14.3 million from UK- and Australia-based institutional and sophisticated investors. This capital injection is set to provide the estimated minimum funding required for its proposed AIM listing next month.
Strategic Financial Moves and Market Expansion
The funds raised will be allocated toward multiple objectives, including redeeming outstanding convertible notes, completing the acquisition of Pain Away, and strengthening working capital. Additionally, the AIM listing is projected to bring financial advantages, including cost savings of $1.4 million by eliminating approximately $12.8 million in debt.
Wellnex Life’s managing director, Zack Bozinovski, highlighted the significance of this development, stating that the proposed admission to AIM will elevate the company’s market presence, enhance credibility, and support the expansion of its brands into the European market.
Momentum Behind Wellnex Life’s Growth
The company’s latest financial performance reflects a strong upward trajectory, with revenue surging by 112% in H1 FY25 compared to the previous period. Brand revenue jumped 182%, while intellectual property (IP) licensing revenue increased by 64%.
Wellnex Life has been actively expanding its portfolio, with its latest milestone being the approval of a new liquid paracetamol plus caffeine soft gel by the Therapeutic Goods Administration. This addition builds upon previous market authorizations for liquid paracetamol, liquid paracetamol plus ibuprofen, and liquid mini-ibuprofen.
Strengthening Global Presence
Wellnex Life is currently engaged in discussions to broaden its IP agreements and expand brand distribution into Europe and the Middle East. The company has also successfully delivered its first product for the UK market, furthering its global licensing deal with Haleon.
With a solid financial foundation and a strategic vision in place, Wellnex Life continues to position itself for long-term growth, leveraging both market expansion and innovation to build on its success.
